Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Anagrelide Hydrochloride

FDA-approved product (capsule, oral), marketed as Agrylin, Anagrelide Hydrochloride.

Registered studies
28
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Anagrelide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Essential thrombocythemia
  • Myeloproliferative disorder
  • Neoplasm
  • Recurrent thrombophlebitis
  • Thrombotic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

28registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Anagrelide Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Anagrelide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers

    NCT01552928 · start 2012-03-29

    Registered record
    Registry ID
    NCT01552928
    Conditions
    Healthy
    Interventions
    Anagrelide 0.5 mg; Anagrelide 2.5 mg; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03-29
    Completion
    2012-07-25
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAnagrelide 0.5 mg; Anagrelide 2.5 mg; Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

    NCT01352585 · start 2011-07-19

    Registered record
    Registry ID
    NCT01352585
    Conditions
    Essential Thrombocythemia (ET)
    Interventions
    Anagrelide hydrochloride
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-07-19
    Completion
    2013-09-19
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia (ET)
    InterventionAnagrelide hydrochloride
    PhaseNot recorded
    Registry statusCompleted

  • Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia

    NCT01230775 · start 2010-12

    Registered record
    Registry ID
    NCT01230775
    Conditions
    Essential Thrombocythaemia
    Interventions
    Anagrelide retard; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2015-01
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythaemia
    InterventionAnagrelide retard; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

    NCT01214915 · start 2010-10-27

    Registered record
    Registry ID
    NCT01214915
    Conditions
    Essential Thrombocythemia (ET)
    Interventions
    Anagrelide Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-27
    Completion
    2012-10-24
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia (ET)
    InterventionAnagrelide Hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

    NCT01243944 · start 2010-10-27

    Registered record
    Registry ID
    NCT01243944
    Conditions
    Polycythemia Vera
    Interventions
    ruxolitinib tablets; Best Available Therapy (BAT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-27
    Completion
    2018-02-09
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera
    Interventionruxolitinib tablets; Best Available Therapy (BAT)
    PhasePhase 3
    Registry statusCompleted

  • Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

    NCT01467661 · start 2010-10-27

    Registered record
    Registry ID
    NCT01467661
    Conditions
    Essential Thrombocythemia (ET)
    Interventions
    SPD422 (anagrelide hydrochloride)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-27
    Completion
    2015-05-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia (ET)
    InterventionSPD422 (anagrelide hydrochloride)
    PhasePhase 3
    Registry statusCompleted

  • Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase

    NCT00481052 · start 2007-06-23

    Registered record
    Registry ID
    NCT00481052
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06-23
    Completion
    2018-04-30
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionNilotinib
    PhasePhase 2
    Registry statusCompleted

  • The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

    NCT00413634 · start 2006-11-13

    Registered record
    Registry ID
    NCT00413634
    Conditions
    Essential Thrombocythaemia
    Interventions
    anagrelide hydrochloride; anagrelide hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-11-13
    Completion
    2008-01-22
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythaemia
    Interventionanagrelide hydrochloride; anagrelide hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

    NCT00202644 · start 2006-01-13

    Registered record
    Registry ID
    NCT00202644
    Conditions
    Thrombocythemia, Hemorrhagic
    Interventions
    Anagrelide; Hydroxyurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-01-13
    Completion
    2015-12-15
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocythemia, Hemorrhagic
    InterventionAnagrelide; Hydroxyurea
    PhasePhase 4
    Registry statusCompleted

  • Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

    NCT00567502 · start 2005-05-31

    Registered record
    Registry ID
    NCT00567502
    Conditions
    Thrombocythemia, Essential
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-05-31
    Completion
    2014-04-30
    Enrolment
    3,647

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocythemia, Essential
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

    NCT00648024 · start 2003-01

    Registered record
    Registry ID
    NCT00648024
    Conditions
    Healthy
    Interventions
    Anagrelide Hydrochloride Capsules 1 mg; Agrylin® Capsules 1 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-01
    Completion
    2003-01
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAnagrelide Hydrochloride Capsules 1 mg; Agrylin® Capsules 1 mg
    PhasePhase 1
    Registry statusCompleted

  • Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

    NCT00648765 · start 2003-01

    Registered record
    Registry ID
    NCT00648765
    Conditions
    Healthy
    Interventions
    Anagrelide Hydrochloride Capsules 1 mg; Agrylin® Capsules 1 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-01
    Completion
    2003-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAnagrelide Hydrochloride Capsules 1 mg; Agrylin® Capsules 1 mg
    PhasePhase 1
    Registry statusCompleted

  • Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

    NCT01065038 · start 2002-09

    Registered record
    Registry ID
    NCT01065038
    Conditions
    Essential Thrombocythaemia
    Interventions
    Anagrelide; Hydroxyurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-09
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythaemia
    InterventionAnagrelide; Hydroxyurea
    PhasePhase 3
    Registry statusCompleted